These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 37658936)
1. Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis. Lloyd-Lavery A Br J Dermatol; 2023 Dec; 190(1):3-4. PubMed ID: 37658936 [No Abstract] [Full Text] [Related]
2. Nemolizumab reduces itch and improves other signs of atopic dermatitis in children aged 6-12 years. Br J Dermatol; 2023 Dec; 190(1):e2. PubMed ID: 38124526 [No Abstract] [Full Text] [Related]
3. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. Kabashima K; Matsumura T; Komazaki H; Kawashima M; N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132 [TBL] [Abstract][Full Text] [Related]
5. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. Kabashima K; Furue M; Hanifin JM; Pulka G; Wollenberg A; Galus R; Etoh T; Mihara R; Nakano M; Ruzicka T J Allergy Clin Immunol; 2018 Oct; 142(4):1121-1130.e7. PubMed ID: 29753033 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. Igarashi A; Katsunuma T; Matsumura T; Komazaki H; Br J Dermatol; 2023 Dec; 190(1):20-28. PubMed ID: 37522351 [TBL] [Abstract][Full Text] [Related]
7. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914 [TBL] [Abstract][Full Text] [Related]
8. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. Ruzicka T; Hanifin JM; Furue M; Pulka G; Mlynarczyk I; Wollenberg A; Galus R; Etoh T; Mihara R; Yoshida H; Stewart J; Kabashima K; N Engl J Med; 2017 Mar; 376(9):826-835. PubMed ID: 28249150 [TBL] [Abstract][Full Text] [Related]
9. Dupilumab alleviates pruritus regardless of skin improvement in adults with atopic dermatitis: A cohort study. Chen YW; Chen HH; Huang WN; Hsu CY; Chen YH; Hung WT; Tang KT J Am Acad Dermatol; 2024 Jan; 90(1):195-196. PubMed ID: 37751779 [No Abstract] [Full Text] [Related]
10. Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Liang J; Hu F; Dan M; Sang Y; Abulikemu K; Wang Q; Hong Y; Kang X Front Immunol; 2022; 13():825312. PubMed ID: 35558086 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis]. Kaneda N Nihon Yakurigaku Zasshi; 2023; 158(3):282-289. PubMed ID: 37121713 [TBL] [Abstract][Full Text] [Related]
12. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249 [TBL] [Abstract][Full Text] [Related]
13. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208 [TBL] [Abstract][Full Text] [Related]
14. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Kabashima K; Matsumura T; Komazaki H; Kawashima M; Br J Dermatol; 2022 Apr; 186(4):642-651. PubMed ID: 34726262 [TBL] [Abstract][Full Text] [Related]
15. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S; N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917 [TBL] [Abstract][Full Text] [Related]